MedTrace Logo

COVID-19 and Venous Thromboembolism Risk

NCT04569344 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 398530

Last updated 2022-11-02

No results posted yet for this study

Summary

Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly reported in patients with severe Covid-19. The aim of this study is evaluate the risk of VTE related to Covid-19 infection in a real-world community-based population.

Conditions

  • Venous Thromboembolism
  • Covid19

Interventions

OTHER

Laboratory test positive for SARS-CoV-2 virus

Exposure/intervention: diagnosis of Covid-19, defined as positive laboratory test for SARS-CoV-2

Sponsors & Collaborators

Principal Investigators

  • Margaret C Fang, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-02-28
Completion
2022-06-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04569344 on ClinicalTrials.gov